

  the total 
Results The total effective rate was 93% and effectual rate 78%. 
结果利培酮治疗首发精神分裂症的临床总有效率为93%,显效率78%。 

RESULTS: At end of the treatment, the total effective rate of risperidon for SC was 91 % and remarkable effective rate was 78 %. 
结果 :利培酮治疗SC的临床总有效率为 91 % ,显效率 78%。 

There were insignificant differences in the decreasing rate of HAMA score and the total clinical effective rate between the study group [(59.03±24.78)%and 72%] and the control group [(57.30±25.33)%and 67%] (P >0.05). 
对照组HAMA减分率为(57.30±25.33)%,临床总有效率为67%,两组比较差异无显著性意义艹卓艹卓艹卓艹卓艹卓(P>0.05)。 

Results The total effective rate was 93% and effectual rate 78%. 
结果 利培酮治疗首发精神分裂症的临床总有效率为 93% ,显效率 78%。 

The total rate of clinical therapeutic response was 70%. 
临床总有效率为 70 %。 

① The decreasing rate of excitement factor score and change of total score of PANSS: At 72 hours after treatment, the total score of excitement factor of PANSS in the Ziprasidone group was significantly reduced as compared with that before treatment, the decreasing rate of score was (47.33 ±26.07)%, and the total clinical effective rate was 47.33%. 
①阴性与阳性症状量表兴奋因子减分率及总分的变化:治疗72h后,甲磺酸齐拉西酮组的阴性与阳性症状量表兴奋因子总分较治疗前明显降低,减分率为(47.33±26.07)%,临床总有效率为47.33%; 

The total score of excitement factor of PANSS in the Haloperidol group was also significantly reduced as compared with that before treatment, the decreasing rate of score was (48.53±21.99)%, and the total clinical effective rate was 48.53%. There were no significant differences between the two groups (P > 0.05). 
氟哌啶醇组阴性与阳性症状量表兴奋因子总分较治疗前同样明显降低,减分率为(48.53±21.99)%,临床总有效率为48.53%,两组比较差异无显著性(P>0.05)。 

Results There were no significant differences of the curative effect(P > 0.05). The reduced rates of PANSS were(60.98± 24.04)% in the subject group and(62.05± 28.31)% in the control group respectively. The total efficiencies were respectively 80.00% in the subject group and 73.33% in the control group after the end of the treatment with zipraside and haloperidol. 
结果治疗结束时PANSS减分率治疗组为(60.98±24.04)%,对照组为(62.05±28.31)%,临床总有效率治疗组为80.00%,对照组为73.33%,组间疗效差异无显著性(P>0.05); 



首页上一页1下一页尾页


